• Brit Long, Summer Chavez, Brandon M Carius, William J Brady, Stephen Y Liang, Alex Koyfman, and Michael Gottlieb.
• SAUSHEC, Emergency Medicine, Brooke Army Medical Center, 3551 Roger Brooke Dr, Fort Sam Houston, TX, USA. Electronic address: Brit.long@yahoo.com.
• Am J Emerg Med. 2022 Jun 1; 56: 158170158-170.

IntroductionCoronavirus disease of 2019 (COVID-19) has resulted in millions of cases worldwide. As the pandemic has progressed, the understanding of this disease has evolved.ObjectiveThis is the second part in a series on COVID-19 updates providing a focused overview of the medical management of COVID-19 for emergency and critical care clinicians.DiscussionCOVID-19, caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. A variety of medical therapies have been introduced for use, including steroids, antivirals, interleukin-6 antagonists, monoclonal antibodies, and kinase inhibitors. These agents have each demonstrated utility in certain patient subsets. Prophylactic anticoagulation in admitted patients demonstrates improved outcomes. Further randomized data concerning aspirin in outpatients with COVID-19 are needed. Any beneficial impact of other therapies, such as colchicine, convalescent plasma, famotidine, ivermectin, and vitamins and minerals is not present in reliable medical literature. In addition, chloroquine and hydroxychloroquine are not recommended.ConclusionThis review provides a focused update of the medical management of COVID-19 for emergency and critical care clinicians to help improve care for these patients.Published by Elsevier Inc.

15 keywords...

hide…